Visual Abstract

Background: The benefits of treating anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) in advancing age remains unclear with most published studies defining elderly as ≥65 years. This study aims to determine outcomes of induction immunosuppression in patients aged ≥75 years. Methods: A cohort of patients aged ≥75 years with a diagnosis of AAV between 2006 and 2018 was constructed from 2 centres. Follow-up was to 2 years or death. Analysis included multivariable Cox regression to compare mortality and end-stage renal disease (ESRD) based on receipt of induction immunosuppression therapy with either cyclophosphamide or rituximab. A systematic review of outcome studies was subsequently undertaken amongst this patient group through Pubmed, Cochrane and Embase databases from inception until October 16, 2019. Results: Sixty-seven patients were identified. Mean age was 79 ± 2.9 years and 82% (n = 55) received induction immunosuppression. Following systematic review, 4 studies were eligible for inclusion, yielding a combined total of 290 patients inclusive of our cohort. The aggregated 1-year mortality irrespective of treatment was 31% (95% CI 25–36%). Within our cohort, induction immunosuppression therapy was associated with a significantly lower 2-year mortality risk (hazard ratio [HR] 0.29 [95% CI 0.09–0.93]). The pooled HR by meta-analysis confirmed this with a significant risk reduction for death (HR 0.31 [95% CI 0.16–0.57], I2 = 0%). Treated patients had a lower pooled rate of ESRD, but was not statistically significant (HR 0.71 [95% CI 0.15–3.35]). Conclusion: This meta-analysis suggests that patients ≥75 years with AAV do benefit from induction immunosuppression with a significant survival benefit. Age alone should not be a limiting factor when considering treatment.

de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis.
Clin J Am Soc Nephrol
. 2013 Oct;8(10):1709–17.
Manno RL, Seo P, Geetha D. Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study.
BMC Nephrol
. 2015 Jun;16(1):88.
Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.
Clin J Am Soc Nephrol
. 2014 May;9(5):905–13.
Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al.; European Vasculitis Study (EUVAS) Group. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis.
Ann Rheum Dis
. 2010 Jun;69(6):1036–43.
Titeca-Beauport D, Francois A, Lobbedez T, Guerrot D, Launay D, Vrigneaud L, et al. Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study.
BMC Nephrol
. 2018 Nov;19(1):317.
Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century – a disease of older patients.
Rheumatology (Oxford)
. 2005 Apr;44(4):495–501.
Haris Á, Polner K, Arányi J, Braunitzer H, Kaszás I, Mucsi I. Clinical outcomes of -ANCA-associated vasculitis in elderly patients.
Int Urol Nephrol
. 2014 Aug;46(8):1595–600.
Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al.; European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis.
Ann Rheum Dis
. 2011 Mar;70(3):488–94.
Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom.
Arthritis Rheum
. 2000 Feb;43(2):414–9.
Watts RA, Al-Taiar A, Scott DG, Macgregor AJ. Prevalence and incidence of Wegener’s granulomatosis in the UK general practice research database.
Arthritis Rheum
. 2009 Oct;61(10):1412–6.
Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa.
Rheumatology (Oxford)
. 2009 Dec;48(12):1560–5.
Moutzouris DA, Herlitz L, Appel GB, Markowitz GS, Freudenthal B, Radhakrishnan J, et al. Renal biopsy in the very elderly.
Clin J Am Soc Nephrol
. 2009 Jun;4(6):1073–82.
Charlson E, Pompei P, Ales K, MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis
. 1987;40(5):373–83.
Ofer-Shiber S, Molad Y. Association of the Charlson comorbidity index with renal outcome and all-cause mortality in antineutrophil cytoplasmatic antibody-associated vasculitis.
Medicine (Baltimore)
. 2014 Nov;93(25):e152.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.
Ann Intern Med
. 1999 Mar;130(6):461–70.
Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al.; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis.
Ann Rheum Dis
. 2009 Mar;68(3):310–7.
de Groot K, Harper L, Jayne D, Suarez L, Gregorini G, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Intern Med
. 2009 May;150(10):670–80.
Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis.
J Am Soc Nephrol
. 2010 Oct;21(10):1628–36.
Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, et al. -ANCA-associated glomerulonephritis in the very elderly.
Kidney Int
. 2011 Apr;79(7):757–64.
Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis.
Clin J Am Soc Nephrol
. 2015 Jul;10(7):1128–35.
Sato S, Yashiro M, Matsuoka N, Asano T, Kobayashi H, Watanabe H, et al. Clinical features and outcomes in patients with elderly-onset anti-neutrophil cytoplasmic antibody-associated vasculitis.
Geriatr Gerontol Int
. 2018 Oct;18(10):1453–7.
Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suárez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Nephrol Dial Transplant
. 2015 Apr;30(Suppl 1):i14–22.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al.; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
N Engl J Med
. 2010 Jul;363(3):221–32.
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al.; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
N Engl J Med
. 2010 Jul;363(3):211–20.
Jayne DR, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al.; CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
J Am Soc Nephrol
. 2017 Sep;28(9):2756–67.
Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A. Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients.
Nephrol Dial Transplant
. 2003 Jul;18(Suppl 5):v5–7.
Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.
Arthritis Rheum
. 2008 Sep;58(9):2908–18.
Hoganson DD, From AM, Michet CJ. ANCA vasculitis in the elderly.
J Clin Rheumatol
. 2008 Apr;14(2):78–81.
Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
Rheumatology (Oxford)
. 2015 Mar;54(3):471–81.
Weiner M, Goh SM, Mohammad AJ, Hrušková Z, Tanna A, Sharp P, et al. Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis.
J Rheumatol
. 2019 Jul;jrheum.190019.
Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Höglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.
Ann Rheum Dis
. 2015 Jan;74(1):177–84.
Nixon AC, Bampouras TM, Pendleton N, Mitra S, Dhaygude AP. Diagnostic Accuracy of Frailty Screening Methods in Advanced Chronic Kidney Disease.
. 2019;141(3):147–55.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.